Paid Clinical Trials - 82,000 Members & Growing

  • Paid Clinical Trials
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.

Sponsored Links







  • Condition:   Fructose Intolerance
    Interventions:   Dietary Supplement: Placedo;   Dietary Supplement: Alanine
    Sponsor:   Augusta University
    Recruiting

  • Conditions:   Muscle Atrophy;   Quality of Life
    Interventions:   Drug: Essential Amino Acids (EAA);   Drug: Placebo (Alanine)
    Sponsors:   University of Oregon;   Slocum Center for Orthopedics and Sports Medicine;   Slocum Research & Education Foundation;   Oregon Research Institute;   Oregon Health and Science University;   University of Arkansas;   National Institute on Aging (NIA)
    Recruiting

  • Condition:   Mild Cognitive Impairment
    Intervention:   Dietary Supplement: N- acetylcysteine plus Glycine v Placebo (alanine)
    Sponsors:   Baylor College of Medicine;   Nantz National Alzhimer's Center, Houston Methodist Hospital, Houston, TX
    Recruiting

  • Condition:   Aging
    Intervention:   Dietary Supplement: Glycine, cysteine (as n-acetylcysteine), alanine
    Sponsors:   Rajagopal V Sekhar;   National Institute on Aging (NIA)
    Recruiting

  • Condition:   Ketosis Prone Diabetes
    Interventions:   Dietary Supplement: arginine;   Dietary Supplement: Citrulline;   Dietary Supplement: Alanine
    Sponsor:   Baylor College of Medicine
    Recruiting

  • Condition:   Renal Insufficiency, Chronic
    Interventions:   Drug: 6R-BH4;   Other: 6R-BH4 placebo;   Dietary Supplement: Folic acid;   Other: Exercise training;   Other: Stretching;   Dietary Supplement: Histidine and beta-alanine supplementation;   Other: Histidine and beta-alanine placebo
    Sponsors:   Emory University;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Gastroparesis;   Dyspepsia
    Interventions:   Drug: Cannabidiol;   Other: placebo
    Sponsor:   Mayo Clinic
    Not yet recruiting

  • Condition:   Ameliorating Oxidative Stress in Type 1 Diabetes
    Interventions:   Drug: N-acetyl cysteine;   Dietary Supplement: omega 6 Fish oil ( PUFA);   Dietary Supplement: Placebo
    Sponsor:   University of Maryland, College Park
    Recruiting

  • Condition:   Adenocarcinoma of the Prostate
    Interventions:   Drug: Muscadine Plus;   Drug: Placebos
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Greater Washington Community Foundation
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Radiation: Total Marrow Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   HLA-DP4 Positive Cells Present;   Platinum-Resistant Ovarian Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Biological: Aldesleukin;   Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes;   Other: Cellular Therapy;   Drug: Melphalan
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Plasma Cell Myeloma;   Secondary Amyloidosis
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Melphalan;   Biological: Daratumumab;   Other: Laboratory Biomarker Analysis
    Sponsors:   City of Hope Medical Center;   Janssen, LP
    Recruiting

  • Conditions:   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia-2;   High Grade Malignant Neoplasm;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Myeloid Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cyclosporine;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mitoxantrone Hydrochloride;   Drug: Mycophenolate Mofetil;   Other: Questionnaire Administration;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Drug: Melphalan Hydrochloride
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Marginal Zone Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Transformed Indolent Non-Hodgkin Lymphoma
    Interventions:   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Venetoclax
    Sponsors:   Ohio State University Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Plasma Cell Leukemia;   Plasmacytoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Panobinostat;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Busulfan;   Drug: Gemcitabine;   Drug: Melphalan;   Drug: Olaparib;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacokinetic Study;   Biological: Rituximab;   Drug: Vorinostat
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aplastic Anemia;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Secondary Myelofibrosis;   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Blasts 15 Percent or Less of Bone Marrow Nucleated Cells;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Glycosylated Recombinant Human G-CSF AVI-014;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Bendamustine;   Drug: Bendamustine Hydrochloride;   Drug: Cyclophosphamide;   Biological: Filgrastim-sndz;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   CD19 Positive;   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Melphalan;   Biological: Rituximab;   Biological: Umbilical Cord Blood-derived Natural Killer Cells
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   B Acute Lymphoblastic Leukemia;   CD22 Positive;   Lymphocytic Neoplasm;   Lymphoma
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Bendamustine;   Biological: Filgrastim-sndz;   Drug: Fludarabine;   Biological: Inotuzumab Ozogamicin;   Drug: Melphalan;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Rituximab;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Indolent Adult Non-Hodgkin Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Lenalidomide;   Drug: Melphalan;   Biological: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With Gene Mutations;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Acute Myeloid Leukemia With Variant MLL Translocations;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Chemotherapy-Related Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Gene Mutation;   Myelodysplastic/Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Biological: Allogeneic Natural Killer Cell Line NK-92;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Autoimmune Disease;   Neurologic Autoimmune Disease;   Autologous Transplant Autoimmune;   Multiple Sclerosis Transplant;   MS Stem Cell Transplant;   Multiple Sclerosis Stem Cell Transplant;   Stiff Person Syndrome;   HCT for Neurologic Autoimmune Disorders;   CIDP Transplant;   Myasthenia Gravis Transplant
    Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Prednisone;   Procedure: Syngeneic Bone Marrow Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HIV Infection;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Plasmablastic Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Follicular Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   High-Risk Neuroblastoma;   NMYC Gene Amplification
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Drug: Isotretinoin;   Drug: Melphalan;   Biological: Sargramostim;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Vincristine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting


PaidClinicalTrials.orgPaidClinicalTrials.org